Date: 2015-09-23
Type of information: Nomination
Compound:
Company: ImaginAb (USA - CA)
Therapeutic area: Technology - Services - Cancer - Oncology
Type agreement: nomination
Action mechanism:
Disease:
Details: * On September 23, 2015, ImaginAb, a clinical-stage immune imaging company, announced the appointment of Jeff Bailey to its board of directors. Mr. Bailey brings nearly three decades of leadership in pharmaceuticals and diagnostic imaging. He most recently served as president and chief executive officer of Lantheus Medical Imaging Inc. At Lantheus, Mr. Bailey oversaw business operations, including strategic partnerships and commercial efforts for more than a dozen marketed imaging products. He also was closely involved in clinical and regulatory efforts for several molecular imaging agents at various stages of development, and has been commended for his ability to grow revenues and margins since assuming the CEO post in January 2013. He retired from Lantheus in August and remains with the company as a consultant. Prior to taking the helm at Lantheus, Mr. Bailey served as chief operating officer of Fougera Pharmaceuticals and chief commercial officer for King Pharmaceuticals. Previously, he led the northwest operating unit team of Novartis Pharmaceuticals as president and general manager. Earlier, he served in key supply chain and commercial leadership roles for Johnson & Johnson including national sales director for Johnson & Johnson subsidiary, Janssen Pharmaceuticals. Mr. Bailey earned a business degree from Rutgers University-New Brunswick. At ImaginAb, Mr. Bailey will work alongside other experienced board members including Dr. Celniker, CEO of Eleven Biotherapeutics; Campbell Murray, M.D., managing director of the Novartis Venture Fund; K. Leonard Judson, president and managing director of Cycad Group, Anna M. Wu, Ph.D., co-founder of ImaginAb and professor in Pathology and Laboratory Medicine at the David Geffen School of Medicine at University of California, Los Angeles; and Isaac Bright, M.D., partner on the Merieux Development management team.
Financial terms:
Latest news:
